Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391872
Status:
COMPLETED
Last Update Posted:
2012-03-13
First Post:
2006-10-23
Brief Title:
A Comparison of Ticagrelor AZD6140 and Clopidogrel in Patients With Acute Coronary Syndrome
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Double-blind Parallel Group Phase 3 Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes ACS PLATO- a Study of PLATelet Inhibition and Patient Outcomes
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PLATO
Brief Summary:
Ticagrelor is a new reversible binding anti-platelet medication Anti-platelet medications work to prevent the formation of blood clots Ticagrelor is being developed as a treatment for patients with acute coronary syndrome ACS ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle Ticagrelor will be compared with clopidogrel to determine which drug when either is used in conjunction with aspirin is better at reducing deaths from vascular causes future heart attacks andor strokes in patients with ACS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PLATO | None | None | None |